Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Correlation of Mutational Profile and Response in Patients with Polycythemia Vera and Essential Thrombocythemia Treated with Pegylated Interferon Alfa 2a As Part of a Prospective Phase II Study

Lucia Masarova, MD, Keyur Patel, MD PhD, Saradhi Mallampathi, PhD, Yawa Dzifa Duose, PhD, Kate J Newberry, PhD, Jorge E. Cortes, MD, Zeev Estrov, MD, Hagop M. Kantarjian, MD, Raja Luthra, Srdan Verstovsek, MD PhD

Blood (2017) 130 (Supplement 1): 1640.

https://doi.org/10.1182/blood.V130.Suppl_1.1640.1640

Published: 2017

Journal Articles

Neoplastic Monocyte-Derived Osteoclasts Are Highly Proliferative, but Sub-Functional in MPN-Associated Myelofibrosis

Ivo Veletic, MD, Taghi Manshouri, C. Cameron Yin, MD PhD, Kate J Newberry, PhD, Srdan Verstovsek, MD PhD, Zeev Estrov, MD

Blood (2017) 130 (Supplement 1): 1664.

https://doi.org/10.1182/blood.V130.Suppl_1.1664.1664

Published: 2017

Journal Articles

Increased Pentraxin-3 Correlates with the Activity of the Neoplastic Clone in Primary Myelofibrosis

Ivo Veletic, MD, Taghi Manshouri, Kate J Newberry, PhD, Joseph E Bove, IV, Ying Zhang, MDMS, Zeev Estrov, MD, Srdan Verstovsek, MD PhD

Blood (2017) 130 (Supplement 1): 5284.

https://doi.org/10.1182/blood.V130.Suppl_1.5284.5284

Published: 2017

Journal Articles

Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation

Kate J. Newberry, Keyur Patel, Lucia Masarova, Rajyalakshmi Luthra, Taghi Manshouri, Elias Jabbour, Prithviraj Bose, Naval Daver, Jorge Cortes, Hagop Kantarjian, Srdan Verstovsek

Blood (2017) 130 (9): 1125–1131.

https://doi.org/10.1182/blood-2017-05-783225

Published: 2017

Includes: Supplemental data

Journal Articles

Cytogenetic Risk Stratification in Primary Versus Post-Essential Thrombocythemia / Post-Polycythemia Vera Myelofibrosis

Lucia Masarova, MD, Prithviraj Bose, MD, Naval G. Daver, MD, Naveen Pemmaraju, MD, Kate J Newberry, PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2016) 128 (22): 4250.

https://doi.org/10.1182/blood.V128.22.4250.4250

Published: 2016

Journal Articles

Histomorphological Responses after Therapy with Pegylated Interferon Alpha-2a in Patients with Essential Thrombocythemia (ET) and Polycythemia Vera (PV)

Lucia Masarova, MD, C. Cameron Yin, MD PhD, Jorge E. Cortes, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Kate J Newberry, PhD, Hagop M. Kantarjian, MD, Carlos E Bueso-Ramos, MD PhD, Srdan Verstovsek, MD PhD

Blood (2016) 128 (22): 4266.

https://doi.org/10.1182/blood.V128.22.4266.4266

Published: 2016

Journal Articles

Clinical Associations of Cytogenetic Abnormalities in Patients with Primary and Post-Essential Thrombocythemia and Post-Polycythemia Vera Myelofibrosis

Lucia Masarova, MD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Kate J Newberry, PhD, Carlos E Bueso-Ramos, MD PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2016) 128 (22): 4265.

https://doi.org/10.1182/blood.V128.22.4265.4265

Published: 2016

Journal Articles

Phase-2 Study of Sotatercept (ACE-011) in Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia

Prithviraj Bose, MD, Naval Daver, MD, Elias J. Jabbour, MD, Allison Pike, RN, Kate J Newberry, PhD, Lingsha Zhou, Sherry Pierce, BSN, BA, Xuemei Wang, MS, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2016) 128 (22): 478.

https://doi.org/10.1182/blood.V128.22.478.478

Published: 2016

Journal Articles

Survival Outcome of Patients with Acute Myeloid Leukemia Transformed from Myeloproliferative Neoplasms

Dai Chihara, MD PhD, Hagop M. Kantarjian, MD, Kate J Newberry, PhD, Farhad Ravandi, MD, Naval G. Daver, MD, Prithviraj Bose, MD, Courtney D. DiNardo, MD MSCE, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Gautam Borthakur, MD, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Uday R. Popat, MD, Jorge E. Cortes, MD, Srdan Verstovsek, MD PhD

Blood (2016) 128 (22): 1940.

https://doi.org/10.1182/blood.V128.22.1940.1940

Published: 2016

Journal Articles

Loss of Normal T-Cell Subset Distribution in Myelofibrosis Is Recovered By the Immunomodulatory Effects of JAK1/2 Inhibition

Sanja Prijic, PhD, Taghi Manshouri, PhD, Ivo Veletic, MD, Kate J Newberry, PhD, Ying Zhang, MD MS, Joseph E Bove, IV, BS, Zeev Estrov, MD, Srdan Verstovsek, MD PhD

Blood (2016) 128 (22): 3138.

https://doi.org/10.1182/blood.V128.22.3138.3138

Published: 2016

Journal Articles

Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis

Lucia Masarova, Wei Wang, Kate J. Newberry, Hagop Kantarjian, Srdan Verstovsek

Blood (2016) 128 (6): 877–880.

https://doi.org/10.1182/blood-2016-03-705012

Published: 2016

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Pegylated Interferon Alpha-2a in Patients with Essential Thrombocythemia and Polycythemia Vera: Results after a Median 7-Year Follow-up of a Phase 2 Study

Lucia Masarova, MD, Srdan Verstovsek, MD, Keyur P. Patel, MD PhD, Kate J Newberry, PhD, Jorge E. Cortes, MD, Gautam Borthakur, MD, Marina Konopleva, MD PhD, Zeev Estrov, MD, Hagop M. Kantarjian, MD

Blood (2015) 126 (23): 60.

https://doi.org/10.1182/blood.V126.23.60.60

Published: 2015

Journal Articles

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib

Keyur P. Patel, Kate J. Newberry, Rajyalakshmi Luthra, Elias Jabbour, Sherry Pierce, Jorge Cortes, Rajesh Singh, Meenakshi Mehrotra, Mark J. Routbort, Madan Luthra, Taghi Manshouri, Fabio P. Santos, Hagop Kantarjian, Srdan Verstovsek

Blood (2015) 126 (6): 790–797.

https://doi.org/10.1182/blood-2015-03-633404

Published: 2015

Includes: Supplemental data

Journal Articles

Ruxolitinib and Lenalidomide As a Combination Therapy for Patients with Myelofibrosis

Daver Naval, MD, Jorge E. Cortes, Elias Jabbour, MD, Naveen Pemmaraju, MD, Nitin Jain, MD, Zeev Estrov, MD, Steven M. Kornblau, MD, Jan A. Burger, MD PhD, Hagop M. Kantarjian, MD, Kate J Newberry, PhD, Srdan Verstovsek, MD PhD

Blood (2014) 124 (21): 1831.

https://doi.org/10.1182/blood.V124.21.1831.1831

Published: 2014

Journal Articles

Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Upregulates SOCS3

Kate J Newberry, PhD, Taghi Manshouri, Ana Livun, Ying Zhang, Rajko Kusec, MD PhD, Srdan Verstovsek, MD PhD

Blood (2014) 124 (21): 1883.

https://doi.org/10.1182/blood.V124.21.1883.1883

Published: 2014

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Correlation of Mutational Profile and Response in Patients with Polycythemia Vera and Essential Thrombocythemia Treated with Pegylated Interferon Alfa 2a As Part of a Prospective Phase II Study

Neoplastic Monocyte-Derived Osteoclasts Are Highly Proliferative, but Sub-Functional in MPN-Associated Myelofibrosis

Increased Pentraxin-3 Correlates with the Activity of the Neoplastic Clone in Primary Myelofibrosis

Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation

Cytogenetic Risk Stratification in Primary Versus Post-Essential Thrombocythemia / Post-Polycythemia Vera Myelofibrosis

Histomorphological Responses after Therapy with Pegylated Interferon Alpha-2a in Patients with Essential Thrombocythemia (ET) and Polycythemia Vera (PV)

Clinical Associations of Cytogenetic Abnormalities in Patients with Primary and Post-Essential Thrombocythemia and Post-Polycythemia Vera Myelofibrosis

Phase-2 Study of Sotatercept (ACE-011) in Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia

Survival Outcome of Patients with Acute Myeloid Leukemia Transformed from Myeloproliferative Neoplasms

Loss of Normal T-Cell Subset Distribution in Myelofibrosis Is Recovered By the Immunomodulatory Effects of JAK1/2 Inhibition

Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis

Efficacy and Safety of Pegylated Interferon Alpha-2a in Patients with Essential Thrombocythemia and Polycythemia Vera: Results after a Median 7-Year Follow-up of a Phase 2 Study

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib

Ruxolitinib and Lenalidomide As a Combination Therapy for Patients with Myelofibrosis

Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Upregulates SOCS3

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only